Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 12/15 08:46:28 pm
73.391 EUR   -0.51%
03:12pDJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
01:01p SANOFI : FDA lifts clinical hold on fitusiran
01:01p SANOFI : FDA lifts clinical hold on fitusiran
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Stocks to Watch: CSX, Aclaris, Alnylam, Rigel

share with twitter share with LinkedIn share with facebook
share via e-mail
12/15/2017 | 03:12pm CET
   By Cara Lombardo 

Companies with shares expected to trade actively in Friday's session include CSX Corp. (>> CSX Corporation), Aclaris Therapeutics Inc. (>> Aclaris Therapeutics Inc), Alnylam Pharmaceuticals Inc. (>> Alnylam Pharmaceuticals, Inc.) and Rigel Pharmaceuticals Inc. (>> Rigel Pharmaceuticals, Inc.).

CSX shares dropped 12% premarket Friday on news that Chief Executive Hunter Harrison was taking a medical leave for an undisclosed illness. The veteran railroad executive's absence puts into question whether or not he will be able to carry out a turnaround at CSX, whose stock had been energized after he was installed.

Aclaris shares rose 1% premarket after the company said it received U.S. Food and Drug Administration approval for its skin-treatment Eskata. Eskata treats non-cancerous skin growths called raised seborrheic keratoses, which affects more than 83 million Americans, according to the company.

Alnylam's stock rose 5% premarket after the company said the U.S. Food and Drug Administration lifted its clinical hold on studies for its hemophilia treatment, fitusiran. Alnylam and the FDA had previously reached an agreement to mitigate risk during studies of the drug, which Alnylam is developing with a unit of Sanofi (>> Sanofi SA).

Rigel shares rose 3.6% premarket after the company said its longtime chief financial officer, Ryan Maynard, would resign at the end of the month. Rigel CEO Raul Rodriguez said recent financing positions the company to prepare for the potential launch of one of its treatments, making it the right time for a transition.

Hess Corp. (>> Hess Corp.) is up 5.5% before the bell on the news the energy company is facing fresh pressure from activist investor Elliott Management, which is hoping to either remove CEO John B. Hess or push him to consider selling all or part of the company.

Adobe Systems Inc. (>> Adobe Systems) rose 2% in premarket action after beating forecasts with its earnings out late Thursday.

Costco Wholesale Corp. (>> Costco Wholesale Corporation) is up 2.7% after the retailer reported fiscal first-quarter earnings and sales above Wall Street forecasts.

Write to Cara Lombardo at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
03:12pDJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
01:29p SANOFI : Solon wants Sanofi, DOH held liable for vaccine mess
01:28p NOBODY KNEW DENGVAXIA POSED RISKS : ex-president Aquino
01:23p SANOFI : Aquino confirms Paris meeting with Sanofi execs over vaccine supply
01:01p SANOFI : FDA lifts clinical hold on fitusiran
01:01p SANOFI : FDA lifts clinical hold on fitusiran
11:22a Germany's Merck in fresh bid to enter U.S. MS pill market
10:30a REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Topline Pivotal Results..
10:30a REGENERON PHARMACEUTICALS : Collaboration Programs Highlighted During Sanofi Ana..
09:20a SANOFI : Noynoy refutes rushed purchase of Dengvaxia vaccine
More news
News from SeekingAlpha
01:12p BIOTECH FORUM DAILY DIGEST : Impacts Of Tax Reform
07:46a FDA lifts clinical hold on Alnylam's fitusiran; shares up 6% premarket
12/14 Sanofi (SNY) Investor Presentation - Slideshow
12/14 Challenge of two Lantus patents commences
12/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 14, 2017
Financials (€)
Sales 2017 35 834 M
EBIT 2017 9 337 M
Net income 2017 8 158 M
Debt 2017 4 979 M
Yield 2017 4,10%
P/E ratio 2017 11,55
P/E ratio 2018 16,02
EV / Sales 2017 2,74x
EV / Sales 2018 2,69x
Capitalization 93 181 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 30
Average target price 84,1 €
Spread / Average Target 14%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.07%109 810
JOHNSON & JOHNSON24.03%380 546
NOVARTIS13.16%222 673
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759